How Ph.D. was paid
$570,992 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| John SimardFormer President & Chief Executive Officer | $1,250,000 | $8,530,442 | $3,000,000 | $12,436 | $30,134,204 |
| Sushma Shivaswamy, Ph.D.Interim Chief Executive Officer & Chief Scientific Officer | $468,557 | $90,000 | — | $12,436 | $570,992 |
| Angela HuDirector of Finance | $200,000 | $40,000 | — | $5,419 | $245,419 |
What changed and why
- $17.3M$17,341,326 severance was paid to John Simard after his December 8, 2025 retirement.
- $8.5M$8,530,442 bonus compensation for Simard included $4,530,442 for 2025 performance.
- $3M$3,000,000 in option awards were granted to Simard during 2025.
- $750K$750,000 annual salary applied to Shivaswamy while serving as interim CEO and chief scientific officer.
- 345:1 was the reported CEO-to-median-employee pay ratio for 2025.
- $87,096$87,096 was the median employee’s 2025 annual total compensation.
Other XBiotech proxy statements
- 2025 proxy statement
John Simard paid $6.2M (+12% on the year), pay ratio 62:1.
Filed Jul 07, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.